C4 Therapeutics opened lower at $2.86, compared with its previous close of $2.89. In the last trading session, the stock traded between $2.64 and $2.86. It showed a downward intraday trend.
An investment of $100 made 5 years ago in C4 Therapeutics is now worth
$ 6.47
Resulting in a loss of
$ 93.53 (93.53%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.11 (-3.91%)
Day High
$2.86
Day Low
$2.64
Day Open
$2.86
Prev Close
$2.89
Volume
42,91,846
1W Return
-11.11%
1M Return
-9.40%
3M Return
-28.13%
6M Return
-12.40%
1Y Return
11.98%
Market Cap ($ Mn)
365
PE Ratio
-
PB Ratio
1.91
PEG Ratio
-
ROE
-52.70%
ROCE
-41.42%
EPS (TTM)
$-0.17
1 Week
-11.11%
1 Month
-9.40%
3 Months
-28.13%
6 Months
-12.40%
9 Months
51.75%
C4 Therapeutics Q3 Results: Loss narrows to $0.16, revenue falls 24.6%
Loss per share narrowed to $0.16 from $0.44 YoY. Quarterly revenue fell 24.59% to $8.468 million. EPS beat analyst consensus estimate by 27.27%. Revenue missed consensus estimate of $8.514 million.
7 days agoC4 Therapeutics advances cemsidomide trial to 100 µg dose after safety clearance
C4 Therapeutics advances Phase 1b trial to 100 µg dose after 75 µg safety clearance. New biomarker data shows cemsidomide prevents T-cell exhaustion in first two patients. Phase 1 data reveals robust T-cell activation and NK cell reprogramming in 62 patients. Enhanced immune function observed at highest doses studied (75 µg and 100 µg). Data from all Phase 1b cohorts expected in mid-2027.
1mo agoC4 Therapeutics to present cemsidomide biomarker data at IMS meeting
C4 Therapeutics to present cemsidomide biomarker data at IMS Annual Meeting. Data covers immunomodulatory effects on T and NK cells in Phase 1 RRMM trial. Results support potential as combination partner with dexamethasone. Presentation scheduled for Glasgow meeting from September 23-26, 2026.
2mo agoC4 Therapeutics Q2 Results: Sales beat estimates by 66 percent
C4 Therapeutics exceeded Q2 expectations with EPS of $(0.18) vs $(0.23) estimate. Sales of $6.641 million beat the $4.000 million forecast by 66.03%, up 2.75% YoY from $6.463 million. Losses narrowed by 51.35% compared to the prior year.
3mo agoC4 Therapeutics grants 162,880 stock options to new employee
C4 Therapeutics granted 162,880 non-qualified stock options to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant vests over four years, with 25% vesting at year one and the remainder monthly. The exercise price matches the closing stock price on August 10, 2026.
3mo agoC4 Therapeutics reports 53% response rate for cemsidomide in Phase 1 trial
C4 Therapeutics presented Phase 1 data for cemsidomide showing a 53% ORR at the 100 µg RP2D in heavily pretreated RRMM patients. The therapy demonstrated deepening responses, including MRD negativity, and was well tolerated with minimal discontinuations.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in C4 Therapeutics is now worth
$ 6.47
Resulting in a loss of
$ 93.53 (93.53%)
Note: Past profits do not guarantee future returns.
